Abbott
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration
Published in TB and Outbreaks Week, March 16th, 2010
Abbott (NYSE:ABT) and Enanta Pharmaceuticals announced the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott. Each antiviral agent will be dosed individually in combination with the current standard of care (SOC).
ABT-450 was discovered as part of an alliance between Abbott and Enanta. ABT-333 and ABT-072, both discovered internally at Abbott, are part of the company's ongoing non-nucleoside...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Emory University
Intestinal bacteria drive obesity and metabolic disease in immune-altered mice - Johns Hopkins University Bloomberg School of Public Health
Mosquitoes -- not birds -- may have carried West Nile virus across US - Wiley-Blackwell
Small wings travel far to spread West Nile virus - Altarum Institute
New Analysis Calls for State and Federal Action to Track Childhood Obesity - Eating Disorders
New eating disorders findings from Hosp University described - Hepatitis
Study data from Dankook University update understanding of hepatitis - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
